danvatirsen: Clinical Trials

6 trials of danvatirsen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 2 terminated. 6 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Active not recruiting 2, Completed 2, Terminated 2
Phase 11Completed 1

Follow danvatirsen: new trials by email Literature Review of danvatirsen trials Research Report on danvatirsen

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Danvatirsen, Pembrolizumab - HNSCC
Phase 2TerminatedFlamingo Therapeutics NV692023-05-302026-01-30
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage
Phase 2CompletedMedImmune LLC842019-03-082022-02-24
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Durvalumab, Danvatirsen, Ceralasertib - Non-Small Cell Lung Cancer
Phase 2Active not recruitingAstraZeneca5282017-12-182025-10-27
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center392017-03-022025-05-06
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
AZD9150, MEDI4736, AZD5069 - Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 / Phase 2CompletedAstraZeneca3402015-08-062026-02-11
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
AZD9150 - Ovarian Cancer, Ovarian Neoplasms
Phase 2TerminatedNational Cancer Institute (NCI)12015-04-032017-05-15

Conditions studied

Carcinoma, Non-Small-Cell Lung (3)  ·  Ascites (1)  ·  Colorectal Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Turcot syndrome (1)

Sponsors

AstraZeneca (2)  ·  Flamingo Therapeutics NV (1)  ·  M.D. Anderson Cancer Center (1)  ·  MedImmune LLC (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (6)  ·  Spain (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Belgium (1)  ·  Israel (1)  ·  Portugal (1)  ·  Switzerland (1)

Top investigators

David S Hong (1)  ·  Dr David Hong, MD (1)  ·  John Heymach, M.D, Ph.D (1)  ·  Nabil Saba, MD (1)  ·  Tim F Greten, M.D. (1)

Results publications

PMID 37707791, PMID 38351187, PMID 39886125

NIH funding

2015 (1), 2017 (1), 2023 (1)